Influence of Vasopressors on Anti-Xa Activity in Critically Ill Patients

Launched by MEDICAL UNIVERSITY OF GDANSK · Sep 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain medications, called vasopressors, affect the effectiveness of a blood thinner known as dalteparin in critically ill patients. Specifically, the researchers want to see if giving patients norepinephrine along with another medication called argipressin makes a difference in how well dalteparin works to prevent blood clots compared to giving norepinephrine alone. This is important because critically ill patients often need both vasopressors to support their blood pressure and anticoagulants to prevent blood clots.

To participate in this trial, patients must be experiencing circulatory failure and receiving norepinephrine, with or without argipressin, while also being treated with dalteparin to prevent blood clots. However, some individuals may not be eligible, including those with certain medical conditions or who are pregnant. Participants will be monitored to understand how effective the blood thinner is in their specific situation. This trial is currently recruiting patients, and all genders aged 18 and older are welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Circulatory failure
• • Supported by continuous infusion of noradrenaline or noradrenaline and argipressin
• • Receiving subcutaneous dalteparin for the prevention of venous thromboembolism.
• Exclusion Criteria:
• • Contraindications for dalteparin
• • Severe coagulopathy
• • Acute or subacute bacterial endocarditis
• • Pregnant women
• • BMI (body mass index) \> 30kg/m2
• • Chronic kidney disease with eGFR (estimated glomerular filtration rate) \< 30 ml/min/1.73 m2
• • Renal replacement therapy
• • The patient died within 52 hours of starting VTE (venous thromboembolism) prophylaxis with dalteparin